Eotaxin (CCL11) Human ProcartaPlex™ Simplex Kit
Eotaxin (CCL11) Human ProcartaPlex™ Simplex Kit
Invitrogen™

Eotaxin (CCL11) Human ProcartaPlex™ Simplex Kit

The Human Eotaxin (CCL11) Simplex ProcartaPlex Kit measures Eotaxin (CCL11) protein and is designed to be combinable with other Simplex了解更多信息
Have Questions?
货号数量
EPX01B-12120-90196 次测试
货号 EPX01B-12120-901
价格(CNY)
-
数量:
96 次测试

The Human Eotaxin (CCL11) Simplex ProcartaPlex Kit measures Eotaxin (CCL11) protein and is designed to be combinable with other Simplex kits so that you can create your own multiplex panel that utilizes Luminex xMAP technology for protein detection/quantitation. When combining multiple Simplex kits (i.e., when you are not using a pre-configured Multiplex Panel), only one buffer kit (sold separately) is needed for each assay plate regardless of plex size.

About ProcartaPlex Assays for the Luminex Platform

ProcartaPlex immunoassays are based on the principles of a sandwich ELISA, using two highly specific antibodies binding to different epitopes of one protein to quantitate all protein targets simultaneously using a Luminex instrument. ProcartaPlex multiplex assays require as little as 25 μL of plasma or serum, or 50 μL of cell culture supernatant, and just four hours to obtain analyzed results.

  • More results per sample—measure multiple protein targets simultaneously in a single 25–50 μL sample
  • Well-established Luminex technology—highly referenced multiplexing platform for protein detection and quantitation

ProcartaPlex assays utilize Luminex xMAP (multianalyte profiling) technology for the simultaneous detection and quantitation of up to 80 protein targets in a single 25–50 μL sample from plasma, serum, cell culture supernatants, and other bodily fluids.

The Luminex beads in the ProcartaPlex assay are internally dyed with precise proportions of red and infrared fluorophores to create spectrally unique signatures that can be identified by the Luminex xMAP detection systems (e.g. Luminex 200, FLEXMAP 3D, and MAGPIX). Similar to a sandwich ELISA, the ProcartaPlex assay uses matched antibody pairs to identify the protein of interest. In a multiplexed assay, each spectrally unique bead is labeled with antibodies specific for a single target protein, and bound proteins are identified with biotinylated antibodies and streptavidin–R-phycoerythrin (RPE). The conjugation of protein-specific antibodies to a distinct bead allows for analysis of multiple targets in a single well.

The most significant difference between a ProcartaPlex assay and ELISA is that the capture antibody in the ProcartaPlex assay is conjugated to a bead and not adsorbed to the microplate well, so the ProcartaPlex assay reagents are free-floating in the solution. For detection, the Luminex 200 instrument, for example, contains two lasers, one to distinguish the spectral signature of each bead and the second to quantify the amount of RPE fluorescence, which is proportional to the amount of protein present in the sample. ProcartaPlex multiplex assays can profile more target proteins using significantly less sample in the same time that it takes to perform a traditional sandwich ELISA.

ProcartaPlex multiplex panels are available in multiple formats across six species (human, mouse, rat, nonhuman primate, porcine, and canine).

规格
测定范围As determined for Lot 1: 0.61 to 2500 pg/mL
检测灵敏度根据批次 1 测定:1.4 pg/mL
磁珠类型Eotaxin (CCL11) [33]
适用于(设备)Luminex™ 仪器
产品规格Simplex 试剂盒
基因C-C 基序趋化因子配体 11
基因别名Scya11
基因 ID (Entrez)6376
基因符号CCL11
产品线ProcartaPlex
蛋白质嗜酸性粒细胞趋化因子
蛋白质子类型C-C 基序趋化因子 11、嗜酸性粒细胞趋化蛋白、小诱导细胞因子 A11
样品类型Serum, Plasma, Cell Culture Supernatants
样品体积Serum, Plasma: 25 μL, CCS: 50 μL
运输条件湿冰
UniProt IDP51671
可组合性可结合使用
产品类型Simplex 试剂盒
数量96 次测试
研究领域Immunology, Oncology, Neurobiology, Toxicology, Chemokines
种属Human
Unit SizeEach
内容与储存

• 1 vial Capture Beads (50X)
• 1 vial biotinylated Detection Antibody (50X)
• 2 vials Human Standard Mix B (lyophilized)

Store at 2°C to 8°C.

常见问题解答 (FAQ)

在我的 ProcartaPlex 检测数据分析过程中,我收到一条警告消息,指出存在高度聚集的珠子。我应该怎么办?

以下是此问题的可能原因和解决方案:
o 检查协议设置(确保选择正确的 DD 设置)。
o 检查鞘液液位并清空废液。
o 在获取板之前,在 Luminex 仪器上运行校准和验证珠。

在我的 ProcartaPlex 检测数据分析期间,珠子落在珠子图上珠子区域的下方或左下方。为什么是这样?

以下是可能的原因和问题的解决方案:

•这通常表明微珠已经光漂白。这个问题也可能由于将微珠暴露于有机溶剂中引起。不幸的是,必须重复该检测,因为微珠不能恢复。必须保护珠子免受光和有机溶剂的影响。
•或者,仪器可能在其测量中关闭,或者可能存在校准问题。致电制造商进行服务预约。

在我的 ProcartaPlex 检测数据分析期间,珠子没有出现在门控区域中。发生了什么?

这表示最后一步使用了不正确的缓冲液。必须使用试剂盒中提供的洗涤液洗涤微珠并在微珠上样至Luminex仪器之前将其重悬。溶液的渗透压将影响微珠的尺寸,而微珠尺寸的任何变化都将改变仪器的检测。

我所有的 ProcartaPlex 检测孔的珠数都不稳定。什么地方出了错?

以下是一些建议:
o 在获取板之前,在 Luminex 仪器上运行校准和验证珠。
o 查看仪器设置并确保它们适合正在运行的检测(调整针高,确保选择正确的珠门和正确的 DD 设置)。
o 在仪器上采集前摇动板以重新悬浮珠子。
o 将珠子涡旋 30 秒,然后再将它们添加到板中。
o 清洗:在清空板之前,不要忘记将板放在手持式磁性洗板机上约 2 分钟。

我的 ProcartaPlex 检测标准曲线的微珠计数正确且规则,但对于我的样品,微珠计数不稳定,我收到一条警告消息,提示“采集中至少有一个区域未达到最大计数”。我应该怎么办?

这种模式表明样本基质效应。以下是一些建议:
o 确认样品已澄清且不含碎片和脂质(建议离心 5-10 分钟)。
o 确认血清、血浆样品的样品与测定稀释剂的比例至少为 1:1。对于细胞裂解物或组织匀浆,确认样品已在测定缓冲液中适当稀释,以将裂解缓冲液中的去污剂浓度降低至≤0.01%。对于其他样品类型,可能需要进一步的样品优化。

引用和文献 (5)

引用和文献
Abstract
Pro-inflammatory cytokines IL-6 and CCL2 suppress expression of circadian gene Period2 in mammary epithelial cells.
Authors:Yu CW, Cheng KC, Chen LC, Lin MX, Chang YC, Hwang-Verslues WW
Journal:Biochim Biophys Acta Gene Regul Mech
PubMed ID:30343691
'Chronic inflammation is known to contribute to tumor initiation and cancer progression. In breast tissue, the core circadian gene Period (PER)2 plays a critical role in mammary gland development and possesses tumor suppressor function. Interleukin (IL)-6 and C-C motif chemokine ligand (CCL) 2 are among the most abundant cytokines in ... More
Evaluation of plasma cytokines in patients with cocaine use disorders in abstinence identifies transforming growth factor alpha (TGFa) as a potential biomarker of consumption and dual diagnosis.
Authors:Maza-Quiroga R, García-Marchena N, Romero-Sanchiz P, Barrios V, Pedraz M, Serrano A, Nogueira-Arjona R, Ruiz JJ, Soria M, Campos R, Chowen JA, Argente J, Torrens M, López-Gallardo M, Marco EM, Rodríguez de Fonseca F, Pavón FJ, Araos P
Journal:PeerJ
PubMed ID:29038767
Cocaine use disorder (CUD) is a complex health condition, especially when it is accompanied by comorbid psychiatric disorders (dual diagnosis). Dual diagnosis is associated with difficulties in the stratification and treatment of patients. One of the major challenges in clinical practice of addiction psychiatry is the lack of objective biological ... More
No difference in human mast cells derived from peanut allergic versus non-allergic subjects.
Authors:Larsen LF, Juel-Berg N, Hansen A, Hansen KS, Mills ENC, van Ree R, Rådinger M, Poulsen LK, Jensen BM
Journal:Immun Inflamm Dis
PubMed ID:29992767
Mast cells are the primary effector cells of allergy. This study aimed at characterizing human peripheral blood-derived mast cells (PBdMC) from peanut allergic and non-allergic subjects by investigating whether the molecular and stimulus-response profile of PBdMC discriminate between peanut allergic and healthy individuals. ... More
Inflammatory mediators and dual depression: Potential biomarkers in plasma of primary and substance-induced major depression in cocaine and alcohol use disorders.
Authors:García-Marchena N, Barrera M, Mestre-Pintó JI, Araos P, Serrano A, Pérez-Mañá C, Papaseit E, Fonseca F, Ruiz JJ, Rodríguez de Fonseca F, Farré M, Pavón FJ, Torrens M
Journal:PLoS One
PubMed ID:30870525
Major depressive disorder (MDD) is the most prevalent comorbid mental disorder among people with substance use disorders. The MDD can be both primary and substance-induced and its accurate diagnosis represents a challenge for clinical practice and treatment response. Recent studies reported alterations in the circulating expression of inflammatory mediators in ... More
Hepatocellular cancer-derived alpha fetoprotein uptake reduces CD1 molecules on monocyte-derived dendritic cells.
Authors:Li C, Song B, Santos PM, Butterfield LH
Journal:Cell Immunol
PubMed ID:30392891
Alpha fetoprotein (AFP) is produced by over 50% of hepatocellular carcinomas (HCC). Uptake of tumor-derived AFP (tAFP) can impair activity of human dendritic cells (DC). The expression pattern of the lipid antigen presenting genes from the CD1 family is reduced in AFP-treated monocyte-derived DC. Surface CD1 family proteins, particularly CD1d, ... More